Vktx nasdaq.

View real-time VKTX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: …Wirestock/iStock via Getty Images. Introduction. Viking Therapeutics (NASDAQ:VKTX) is a clinical-stage biotech firm working on treatments for metabolic and endocrine issues.Their main drug, VK2809 ...A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VKTX shares currently have a short interest ratio of 9.0. Learn More on Viking Therapeutics's short interest ratio.Dec 4, 2023 · Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have covered the stock in the […] 12.28 USD. +6.23%. +8.96%. +30.64%. Nov. 14. Viking Therapeutics' Phase 2b of VK2809 to Treat Non-Alcoholic Steatohepatitis Meets Primary Endpoint; Shares Rise Early. MT. …

Of the funds tracked by Insider Monkey, Peter S. Park's Park West Asset Management has the largest position in Viking Therapeutics, Inc. (NASDAQ:VKTX), worth close to $12 million, accounting for 0 ...צפה בגרף ‎Viking Therapeutics, Inc.‎ בזמן אמת כדי לעקוב אחר תנועת מחיר המניה. תמצא תחזיות שוק, ‎VKTX‎ וחדשות שוק כלכליות.Research Viking Therapeutics' (Nasdaq:VKTX) stock key valuation metrics while comparing it with its industry peers & market side by side. Dashboard Markets Discover Watchlist Portfolios Screener Viking Therapeutics, Inc.

View Premium Services. Real time Viking Therapeutics (VKTX) stock price quote, stock graph, news & analysis.VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...

VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83.Viking Therapeutics Inc (NASDAQ:VKTX) trade information. Sporting 10.61% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Friday, 12/01/23 when the VKTX stock price touched $14.39 or saw a rise of 3.62%. Year-to-date, Viking Therapeutics Inc shares have moved 53.09%, while the 5 …Next on this list of stocks that analysts love is Viking Therapeutics (NASDAQ: VKTX ). The stock has been rated by 11 analysts in the last three months with 10 of them giving VKTX stock a Strong ...Mar 19, 2023 · VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 83% based on the firm’s underlying fundamentals and the stock ... Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports.Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have covered …

Feb 9, 2023 · Average portfolio weight of all funds dedicated to VKTX is 0.02%, a decrease of 20.95%. Total shares owned by institutions decreased in the last three months by 1.25% to 27,896K shares.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company.

May 11, 2023 · As of May 11, 2023, the average one-year price target for Viking Therapeutics is 29.89. The forecasts range from a low of 23.23 to a high of $36.75. The average price target represents an increase ... Nasdaq Futures. 15,979.75 ... (NASDAQ:VKTX), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 74% ownership. That ...Viking Therapeutics' (NASDAQ:VKTX) shares rose 14% after clinical results from a Phase 1 trial on its obesity drug, VK2735, were released. The study showed that VK2735, a dual agonist of GLP-1 and ...Strong Quarter-End Cash Position of $393M. SAN DIEGO, July 26, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the ...Strong Quarter-End Cash Position of $393M. SAN DIEGO, July 26, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the ...Viking Therapeutics Inc (Symbol: VKTX) saw options trading volume of 5,067 contracts, representing approximately 506,700 underlying shares or approximately 53.5% of VKTX's average daily trading ...VKTX Latest Real Time Trades ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, and more asset classes. /

Dec 4, 2023 · Viking Therapeutics Inc (NASDAQ:VKTX)’s Major holders. Insiders own 5.89% of the company shares, while shares held by institutions stand at 68.75% with a share float percentage of 73.05%. Investors are also buoyed by the number of investors in a company, with Viking Therapeutics Inc having a total of 246 institutions that hold shares in the ... VKTX Price Action: Viking Therapeutics is making new 52-week highs on Monday. The stock was up 46.2% at $5.88 at time of publication, according to Benzinga Pro. Photo: Konstantin Kolosov from Pixabay.18 oct 2023 ... Viking Therapeutics (NASDAQ:VKTX) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a ...May 16 (Reuters) - Viking Therapeutics Inc VKTX.O said on Tuesday its experimental drug, VK2809, met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease.Find the latest Madrigal Pharmaceuticals, Inc. (MDGL) stock quote, history, news and other vital information to help you with your stock trading and investing.May 18, 2023 · NASDAQ: VKTX Viking Therapeutics. Market Cap. $1B. Today's Change (-2.28%) -$0.28. ... (VKTX-2.28%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's ...

Nasdaq Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology platform allows you to search, discover and access ...

Viking Therapeutics Inc stock price (VKTX) NASDAQ: VKTX. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Viking Therapeutics Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Find the latest Earnings Report Date for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com. VKTX NASDAQ: $20: $7-9 2,500,000: Laidlaw & Company: Developing drugs to speed hip fracture recovery and treat various metabolic disorders. Click to enlarge. IPO pipeline update.Jul 10, 2023 · Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our Quantitative Momentum Investor model based on the ... The latest price target for . Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023.The analyst firm set a price target for 32.00 expecting VKTX to rise ...Viking Therapeutics (NASDAQ: VKTX) stock is climbing higher on Tuesday after initiating a Phase 1 clinical trial of VK2735. VK2735 is a dual glucagon-like peptide 1 (GLP-1) and “glucose ...Price Volume Sep '23 Oct '23 Nov '23 Dec '23 $10 $8 $12 $14 $16 $18 0M 10M 20M 2020. Display Events. Dividends. Splits. Earnings. News. Chart Style. Line. Mountain.Rhumbline Advisers acquired a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 127,829 shares of the biotechnology company’s stock, valued at approximately $2,072,000. Rhumbline …Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. ... VKTX. $12.01 (-2.24%) $0.28 *Average returns of all recommendations since inception. Cost basis and ...Here's why they chose Bluebird Bio (NASDAQ: BLUE), Travere Therapeutics (NASDAQ: TVTX), and Viking Therapeutics (NASDAQ: VKTX). The upside is huge, but beware of the risks .

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2023 Earnings Conference Call April 26, 2023 4:30 PM ETCompany Participants. Stephanie Diaz - Manager of Investor Relations. Brian Lian - Viking’s ...

NASDAQ: Viking Therapeutics Inc (VKTX) = 11.83 USD. Provided by Alpha Vantage. Viking Therapeutics Inc stock (VKTX) in USD. 1 VKTX = 11.83 USD. 1 month. 6 months. 1 year. 5 years. Hold over 40 currencies to convert and send money at any time. Open an account.

Dec 1, 2023 · Viking Therapeutics last announced its quarterly earnings data on October 25th, 2023. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.01. Viking Therapeutics has generated ($0.93) earnings per share over the last year ( ($0.93) diluted earnings per share). The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics ( VKTX -2.28%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares ...Shares of Viking Therapeutics, Inc. (VKTX) have gained 1.5% over the past four weeks to close the last trading session at $6.14, but there could still be a solid upside left in the stock if short ...Based on analysts offering 12 month price targets for VKTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . NASDAQ:VKTX 13.01. 0.79 (6.46%) 1d Financials Technical Analysis 1w 1m 6m 1y Interactive chart Dec 1, 2023, 9:00 pm 0 This is a Panic-proof Portfolio opinion which is available only for Premium members Curated by Michael O'Reilly since 2020. 1550+ opinions with 4.81 rating (one of ...VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ... The latest price target for Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023. The analyst firm set a price target ...Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and …

Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added 15% on Monday after Roche (OTCQX:RHHBY) agreed to acquire a peer obesity drugmaker Carmot Therapeutics in a up to $3.1B deal. Viking ... May 11, 2023 · As of May 11, 2023, the average one-year price target for Viking Therapeutics is 29.89. The forecasts range from a low of 23.23 to a high of $36.75. The average price target represents an increase ... VKTX-3.57%. MDGL -0.85%. SPX-0.20% ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange ...Average portfolio weight of all funds dedicated to VKTX is 0.08%, an increase of 365.99%. Total shares owned by institutions increased in the last three months by 26.65% to 35,130K shares.Instagram:https://instagram. us ecn forex brokersoklahoma gas and electric stock pricebest account to trade optionsbest va refinance lender In trading on Tuesday, shares of Viking Therapeutics Inc (Symbol: VKTX) entered into oversold territory, hitting an RSI reading of 25.3, after changing hands as low as $15.06 per share. By ...Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta ... llc for day tradingbest medicaid plan in pa EPS Estimate Trends. Current. N/A. 1 Month Ago. -$0.24. 3 Months Ago. -$0.24. Viking Therapeutics Inc. analyst estimates, including VKTX earnings per share estimates and analyst recommendations.VKTX NASDAQ: $20: $7-9 2,500,000: Laidlaw & Company: Developing drugs to speed hip fracture recovery and treat various metabolic disorders. Click to enlarge. IPO pipeline update. best ev stocks to invest in May 16 (Reuters) - Viking Therapeutics Inc VKTX.O said on Tuesday its experimental drug, VK2809, met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease.Find the latest press releases from Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.